CHARLES CLEELAND to United States
This is a "connection" page, showing publications CHARLES CLEELAND has written about United States.
Connection Strength
0.488
-
Determination of mild, moderate, and severe pain interference in patients with cancer. Pain. 2017 06; 158(6):1108-1112.
Score: 0.045
-
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol. 2013 Nov; 14(12):1193-9.
Score: 0.035
-
Levels of symptom burden during chemotherapy for advanced lung cancer: differences between public hospitals and a tertiary cancer center. J Clin Oncol. 2011 Jul 20; 29(21):2859-65.
Score: 0.030
-
Caregiver symptom burden: the risk of caring for an underserved patient with advanced cancer. Cancer. 2011 Mar 01; 117(5):1070-9.
Score: 0.028
-
Assessing the Symptoms of Cancer Using Patient-Reported Outcomes (ASCPRO): searching for standards. J Pain Symptom Manage. 2010 Jun; 39(6):1077-85.
Score: 0.027
-
Development and initial validation of the thyroid cancer module of the M. D. Anderson Symptom Inventory. Oncology. 2009; 76(1):59-68.
Score: 0.025
-
Assessing persistent cancer pain: a comparison of current pain ratings and pain recalled from the past week. J Pain Symptom Manage. 2009 Feb; 37(2):168-74.
Score: 0.024
-
Health-related quality of life and symptom assessment in clinical research of patients with hematologic malignancies: where are we now and where do we go from here? Haematologica. 2007 Dec; 92(12):1596-8.
Score: 0.023
-
People in pain: how do they seek relief? J Pain. 2007 Aug; 8(8):624-36.
Score: 0.022
-
Pain, depression, and fatigue in community-dwelling adults with and without a history of cancer. J Pain Symptom Manage. 2006 Aug; 32(2):118-28.
Score: 0.021
-
Rapid improvement in pain management: the Veterans Health Administration and the institute for healthcare improvement collaborative. Clin J Pain. 2003 Sep-Oct; 19(5):298-305.
Score: 0.017
-
Greek brief pain inventory: validation and utility in cancer pain. Oncology. 2001; 60(1):35-42.
Score: 0.014
-
Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Clin Trials. 2021 02; 18(1):104-114.
Score: 0.014
-
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. J Immunother Cancer. 2020 10; 8(2).
Score: 0.014
-
Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop. Value Health. 2018 06; 21(6):742-747.
Score: 0.011
-
Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE. Clin Trials. 2017 Jun; 14(3):255-263.
Score: 0.011
-
Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling. Pain. 1996 Oct; 67(2-3):267-73.
Score: 0.011
-
Enhancing quality of life as a goal for anticancer therapeutics. Sci Transl Med. 2016 06 22; 8(344):344ed9.
Score: 0.010
-
Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG-ACRIN's Symptom Outcomes and Practice Patterns study. Cancer. 2016 02 01; 122(3):438-46.
Score: 0.010
-
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol. 2015 Nov; 1(8):1051-9.
Score: 0.010
-
When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995 May; 61(2):277-284.
Score: 0.010
-
Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014 Sep; 106(9).
Score: 0.009
-
Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst. 2011 Dec 21; 103(24):1851-8.
Score: 0.008
-
ASCPRO recommendations for the assessment of fatigue as an outcome in clinical trials. J Pain Symptom Manage. 2010 Jun; 39(6):1086-99.
Score: 0.007
-
Impact of cultural and linguistic factors on symptom reporting by patients with cancer. J Natl Cancer Inst. 2010 May 19; 102(10):732-8.
Score: 0.007
-
The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations. Pain Med. 2010 Mar; 11(3):337-46.
Score: 0.007
-
Multidimensional measurement of cancer pain: comparisons of US and Vietnamese patients. J Pain Symptom Manage. 1988; 3(1):23-7.
Score: 0.006
-
Patient-reported outcomes: instrument development and selection issues. Value Health. 2007 Nov-Dec; 10 Suppl 2:S86-93.
Score: 0.006
-
Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations. Pain. 2006 Dec 05; 125(3):208-215.
Score: 0.005
-
Pain in aging community-dwelling adults in the United States: non-Hispanic whites, non-Hispanic blacks, and Hispanics. J Pain. 2007 Jan; 8(1):75-84.
Score: 0.005
-
Epidural and intrathecal analgesia is effective in treating refractory cancer pain. Pain Med. 2004 Sep; 5(3):239-47.
Score: 0.005
-
Documentation of pain in comprehensive cancer centers in the United States: a preliminary analysis. J Natl Compr Canc Netw. 2004 Mar; 2(2):173-80.
Score: 0.004
-
Greek M.D. Anderson Symptom Inventory: validation and utility in cancer patients. Oncology. 2004; 67(3-4):203-10.
Score: 0.004
-
The role of the American Society of Clinical Oncology in cancer control worldwide. J Clin Oncol. 1995 Jan; 13(1):300.
Score: 0.002